We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

TroVax Renal Immunotherapy Survival Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00397345
Recruitment Status : Completed
First Posted : November 9, 2006
Last Update Posted : October 19, 2020
Information provided by (Responsible Party):
Oxford BioMedica

Brief Summary:
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.

Condition or disease Intervention/treatment Phase
Clear Cell Renal Carcinoma Biological: Trovax Biological: Placebo Biological: Standard of care therapy Phase 3

Detailed Description:

This is an international, randomised, double blind, placebo controlled, parallel group study to investigate whether a minimum of three doses of TroVax® added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic renal clear cell adenocarcinoma.

The primary endpoint is survival. The study is designed to be pragmatic, limiting additional study related investigations to a minimum. Protocol mandated scans and X-rays are limited to two time points (baseline and week 26) to permit comparison of the percentage of patients with progressive disease at 6 months as a secondary efficacy endpoint. Six months was selected based on review of published literature indicating that progressive disease was commonly observed by 26 weeks in patients with renal cancer. Endpoints such as tumour response by RECIST are considered of secondary importance to survival and will be determined by radiological examinations ordered at the discretion of the investigator based on the clinical status of the patient and will be based the interpretation of the patient's care-team (investigator and local radiologist).

After signing the study informed consent form and meeting the baseline enrolment criteria patients will be assigned by the investigator (their physician) to one of the following defined first-line standard of care regimens based on what is best for the patient and consistent with local practice:

  1. subcutaneous low dose IL-2
  2. interferon-α (excluding pegylated IFNα)
  3. sunitinib

TroVax® is administered at a dose of 1E9TCID50/ml in 1ml by injection into the deltoid muscle of the upper arm at regular intervals up to 8 weeks apart up to a maximum of 13 doses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 733 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.
Study Start Date : September 2006
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Arm Intervention/treatment
Experimental: Trovax Biological: Trovax
1ml IM injection 2-8 weeks apart.

Biological: Standard of care therapy
subcutaneous low dose IL-2, interferon-α or sunitinib

Placebo Comparator: Placebo Biological: Placebo

Biological: Standard of care therapy
subcutaneous low dose IL-2, interferon-α or sunitinib

Primary Outcome Measures :
  1. overall survival [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent. The patient must be competent to give written informed consent and comply with the protocol requirements.
  • Locally advanced or metastatic, histologically proven clear cell renal carcinoma.
  • Primary tumour surgically removed (some residual advanced primary tumour may remain).
  • At least four weeks post surgery or radiotherapy.
  • First-line. No prior therapy for renal cancer except surgery or radiotherapy.
  • Measurable disease.
  • Aged 18 years or more.
  • Patient expected to survive a minimum of 12 weeks (i.e. in the opinion of the investigator there is a >90% probability that the patient will survive >12 weeks if treated with the selected standard of care).
  • Free of clinically apparent autoimmune disease (including no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, insulin dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease).
  • Total white cell count ≥ 3 x 109/L and lymphocyte count ≥1 x 109/L.
  • Serum creatinine ≤1.5 times the upper limit of normal.
  • Bilirubin ≤ 2 times the upper limit of normal and an SGPT of ≤ 4 times the upper limit of normal.
  • Women must be either post menopausal, or rendered surgically sterile or, if of child bearing potential, must have been practising a reliable form of contraception (oral contraception + a barrier method) for at least three months prior to the first dose of TroVax® and must continue while they are being treated with TroVax®. Men must practise a reliable form of contraception (barrier or vasectomy) while they are being treated with TroVax®.
  • No acute changes on 12-lead ECG.
  • Ejection fraction documented as not less than 45% or no clinical suspicion that cardiac ejection fraction is less than 45%.(If clinical suspicion exists the ejection fraction should be measured according to local site procedures).
  • Karnofsky performance status of ≥ 80%.

Exclusion Criteria:

  • Cerebral metastases. (Known from previous investigations or clinically detectable).
  • Previous exposure to TroVax®.
  • Serious infections within the 28 days prior to entry to the trial.
  • Known to test positive for HIV or hepatitis B or C.
  • Life threatening illness unrelated to cancer.
  • History of allergic response to previous vaccinia vaccinations.
  • Known allergy to egg proteins.
  • Known hypersensitivity to neomycin.
  • Participation in any other clinical trial of a licensed or unlicensed drug within the previous 30 days or during the course of this trial.
  • Previous malignancies within the last 10 years other than successfully treated squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy.
  • Previous history of major psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide informed consent or to comply with the protocol.
  • Oral corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency.
  • Ongoing use of agents listed in locally approved prescribing information as causing immunosuppression.
  • Prior history of organ transplantation.
  • Pregnancy or lactation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00397345

Show Show 152 study locations
Sponsors and Collaborators
Oxford BioMedica
Publications of Results:
Layout table for additonal information
Responsible Party: Oxford BioMedica
ClinicalTrials.gov Identifier: NCT00397345    
Other Study ID Numbers: TV3/001/06
First Posted: November 9, 2006    Key Record Dates
Last Update Posted: October 19, 2020
Last Verified: October 2020
Keywords provided by Oxford BioMedica:
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases